Landmark Study Finds Intraoperative PET-CT Significantly Reduces Re-Operation Rates in Breast-Conserving Surgery

For decades, breast-conserving surgery—commonly known as a lumpectomy—has relied on a delicate balance between removing a tumor and preserving healthy tissue. The surgeon's goal is to excise the cancerous mass with a microscopic border of healthy cells, known as a 'negative margin.' However, because surgeons cannot see microscopic cancer cells with the naked eye, they must operate based on preoperative imaging and tactile feedback. The excised tissue is then sent to a pathology laboratory, where it is inked, sliced, and examined under a microscope. This gold-standard process takes several days, leaving the patient in a state of anxious limbo, waiting for a phone call to confirm whether the surgery was truly successful.[5]

The psychological and physical toll of that waiting period is profound, primarily because the news is frequently bad. Under current standard-of-care practices, between 20 and 30 percent of breast-conserving surgeries result in a 'positive margin,' meaning cancer cells extend to the very edge of the removed tissue. When this occurs, it indicates that residual cancer likely remains in the breast, significantly increasing the risk of local recurrence. The standard medical response is a mandatory second operation—a re-excision—to clear the remaining cancer. This means a second round of anesthesia, additional surgical trauma, delayed radiation therapy, and compounding emotional distress for the patient.[5]

A landmark prospective trial published in late June 2026 in JAMA Surgery offers a definitive solution to this enduring clinical blind spot. The Breast cancer Intraoperative Margin Assessment (BrIMA) study, led by researchers at the Cancer Research Institute Ghent in Belgium, represents the largest multicenter evaluation of intraoperative molecular imaging to date. The trial investigated whether scanning the excised tumor tissue inside the operating room could provide surgeons with the immediate feedback necessary to achieve clear margins on the first attempt. The results demonstrate a paradigm shift in surgical oncology, proving that real-time molecular mapping can virtually eliminate the need for second surgeries.[1][2]

The technological centerpiece of the BrIMA study is a compact, mobile imaging device known as the AURA 10, developed by the Belgian medical technology firm XEOS. Unlike traditional, room-sized PET-CT scanners that require dedicated lead-lined bunkers in radiology departments, this system is designed specifically for the surgical suite. It allows the surgical team to perform high-resolution molecular and anatomical imaging of the excised tissue specimen while the patient is still under anesthesia. By bringing the diagnostic power of nuclear medicine directly to the point of surgery, the technology collapses a multi-day waiting period into a matter of minutes.[4][5]

The mechanism relies on a well-established radiotracer known as 18F-fluorodeoxyglucose (18F-FDG), a radioactive form of glucose. Shortly before the operation begins, the patient receives a low-dose intravenous injection of the tracer. Because cancer cells are highly metabolically active, they consume glucose at a much faster rate than surrounding healthy breast tissue. The 18F-FDG accumulates preferentially within the malignant cells, effectively causing the tumor to 'light up' on a molecular level. This metabolic contrast provides the foundation for the highly sensitive imaging that follows the physical excision of the mass.

Once the surgeon removes the primary tumor specimen, it is immediately placed into the intraoperative PET-CT scanner located just steps from the operating table. Within ten minutes, the device generates a detailed, three-dimensional map of the tissue. The computed tomography (CT) component provides the anatomical structure, while the positron emission tomography (PET) component highlights the exact location of the radiotracer. If the glowing boundary of the tumor touches the edge of the excised tissue on the monitor, the surgeon instantly knows that the margin is positive and can immediately remove additional targeted tissue from the patient's breast cavity.[1]

The clinical efficacy of this approach, as detailed in the JAMA Surgery publication, is striking. The BrIMA trial enrolled 148 patients across six European breast cancer centers. For patients with invasive ductal carcinoma—the most common form of breast cancer—the success rate for clearing margins on the first attempt was 83.3 percent when no intraoperative assessment was used. When surgeons utilized the intraoperative PET-CT system, the success rate surged to 95.2 percent. This near-total clearance rate represents a massive reduction in the statistical likelihood of a patient requiring a follow-up re-excision procedure.[1][2]

The study also compared the novel imaging technique against standard-of-care intraoperative margin assessment methods, such as two-dimensional specimen radiography or frozen section analysis. Across all breast cancer subtypes included in the trial, standard techniques achieved an 81.8 percent success rate. The specimen PET-CT imaging significantly outperformed these conventional methods, elevating the overall success rate to 91.9 percent. The researchers noted that the three-dimensional molecular view provided a depth of clarity that traditional flat x-rays simply could not match, particularly in dense breast tissue where tumor boundaries are notoriously difficult to discern.[1]

Crucially, the intraoperative PET-CT system proved adept at finding hidden threats. In the BrIMA study, the imaging influenced intraoperative decision-making by identifying positive margins in 17.5 percent of the patients. More importantly, in nearly 13 percent of the cases, the PET-CT scan detected positive margins that standard-of-care assessments had completely missed. Without the molecular imaging, those patients would have had their incisions closed, only to be called back to the hospital a week later when the final pathology report revealed the residual disease.[1][5]

The translation of this European research into American clinical practice is already underway. In late June 2026, Vanderbilt University Medical Center in Nashville, Tennessee, announced that it had become the first institution in the United States to successfully utilize intraoperative PET-CT imaging for a breast cancer resection. The milestone marks a critical step in the domestic adoption of the technology, signaling to other major US cancer centers that the workflow is not only feasible but highly beneficial for patient outcomes.[3]

Dr. Denise Garcia, the surgical oncologist who led the pioneering procedure at Vanderbilt Health, emphasized the profound impact on patient peace of mind. By utilizing the mobile scanner to verify the complete removal of the cancerous mass in real-time, her team was able to conclude the surgery with absolute confidence. Garcia noted that the application of intraoperative PET-CT proves that countless patients can benefit from the expansion of this methodology, ensuring that surgeries are completed with precision and sparing women the anxiety of waiting for postoperative pathology results.[3]

Integrating a radioactive tracer and a PET-CT scanner into a sterile operating room does require logistical adjustments, but the BrIMA trial data suggests the hurdles are manageable. The study reported that the workflow had minimal impact on routine surgical practice and patient flow. Because the imaging occurs concurrently while the surgeon is achieving hemostasis—controlling bleeding in the surgical cavity—the ten-minute scan does not significantly prolong the total time the patient spends under anesthesia. Furthermore, the high degree of interobserver agreement among surgeons reading the scans indicates that the images are intuitive and actionable.[1][5]

Radiation safety, a primary concern when introducing nuclear medicine into the surgical suite, was also rigorously evaluated. The protocol utilizes a micro-dose of 18F-FDG—approximately 0.8 to 1.0 MBq per kilogram of patient weight—which is substantially lower than the dose used for standard diagnostic whole-body PET scans. Dosimetry monitoring throughout the trials confirmed that the radiation exposure to the surgical staff, including surgeons and instrumenting nurses, remained exceptionally low and well within strict occupational safety limits.

Despite the overwhelming clinical benefits, the widespread adoption of intraoperative PET-CT faces structural and economic challenges. The transparent uncertainty surrounding the technology centers on its upfront capital costs, the availability of the specialized mobile scanners, and the technical requirements of handling radiotracers in surgical environments. Currently, the logistics of coordinating with a nuclear medicine pharmacy to deliver the short-lived 18F-FDG tracer precisely at the time of surgery may restrict the technology to specialized, high-volume academic cancer centers, leaving community hospitals waiting for broader logistical solutions.[1][5]

Nevertheless, the validation of intraoperative PET-CT in breast-conserving surgery represents a watershed moment for surgical oncology. By successfully bridging the gap between molecular imaging and real-time surgical intervention, the medical community is moving closer to a future where the phrase 'we didn't get it all' becomes a relic of the past. As the technology scales and clinical workflows adapt, the immediate verification of clear margins promises to elevate the standard of care, ensuring that the first surgery is the only surgery required to cure early-stage breast cancer.[5]